Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

527
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
527
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

3.4K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.4K
Glaucoma: Overview01:25

Glaucoma: Overview

702
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
702
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

628
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
628
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.2K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unraveling the immune-microbial axis in chronic ocular surface disease.

Current opinion in allergy and clinical immunology·2025
Same author

Bridging diagnostic gaps in anterior ocular inflammatory surface diseases.

Current opinion in allergy and clinical immunology·2025
Same author

From innovation to implementation: strengthening anterior ocular inflammatory surface diseases diagnostics through global health policy.

Current opinion in allergy and clinical immunology·2025
Same author

The Link Between Allergic Rhinitis and Keratoconus: A Call for Greater Awareness, Early Intervention, and Future Ocular Surface Diagnostic Tools.

The journal of allergy and clinical immunology. In practice·2024
Same author

The collaborative medical practice of the ocular surface: a major role of the allergist/immunologist.

Current opinion in allergy and clinical immunology·2024
Same author

Ocular surface disorders: office procedures for the allergist/clinical immunologist.

Current opinion in allergy and clinical immunology·2024
Same journal

Biosimilars in allergology: an outline in pediatric patients.

Current opinion in allergy and clinical immunology·2026
Same journal

The immunogenetic landscape of systemic lupus erythematosus.

Current opinion in allergy and clinical immunology·2026
Same journal

Circadian control of innate immunity: molecular mechanisms and implications for allergic disorders.

Current opinion in allergy and clinical immunology·2026
Same journal

Probiotics in allergic disease: from adjunct supplement to immune-modifying strategy (2026 update).

Current opinion in allergy and clinical immunology·2026
Same journal

Updates on drug-induced anaphylaxis in children.

Current opinion in allergy and clinical immunology·2026
Same journal

Beta-lactam de-labelling as a core antimicrobial stewardship strategy in the era of the antimicrobial resistance pandemic: a narrative review.

Current opinion in allergy and clinical immunology·2026
See all related articles

Related Experiment Video

Updated: Aug 29, 2025

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.4K

Immunobiologicals and ocular surface disease.

Leonard Bielory1

  • 1Department of Medicine, Allergy, Immunology and Ophthalmology, Hackensack Meridian School of Medicine, Center of Environmental Prediction, Rutgers University, Center for Aerobiological Research, Kean University, Newark, New Jersey, USA.

Current Opinion in Allergy and Clinical Immunology
|September 12, 2022
PubMed
Summary
This summary is machine-generated.

Immunobiologicals offer targeted treatment for inflammatory eye conditions. Research explores their efficacy and safety for ocular surface disorders, expanding therapeutic options beyond traditional steroids.

More Related Videos

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

310
Conjunctival Commensal Isolation and Identification in Mice
07:52

Conjunctival Commensal Isolation and Identification in Mice

Published on: May 1, 2021

4.5K

Related Experiment Videos

Last Updated: Aug 29, 2025

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.4K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

310
Conjunctival Commensal Isolation and Identification in Mice
07:52

Conjunctival Commensal Isolation and Identification in Mice

Published on: May 1, 2021

4.5K

Area of Science:

  • Ophthalmology
  • Immunology
  • Pharmacology

Background:

  • Immunobiologicals are increasingly used for immune-based inflammatory disorders.
  • Current applications span autoimmune conditions, transplantation, and atopic diseases like asthma and dermatitis.

Purpose of the Study:

  • To review the role of immunobiologicals in treating ocular inflammatory disorders.
  • To assess the impact of immunobiologicals on the ocular surface.
  • To explore immunobiologicals as alternatives to glucocorticosteroids for chronic eye inflammation.

Main Methods:

  • Review of clinical studies and literature on immunobiologicals in ophthalmology.
  • Analysis of reported adverse effects on the ocular surface.
  • Evaluation of therapeutic potential for chronic ocular surface and intraocular inflammatory conditions.

Main Results:

  • Immunobiologicals show potential for treating various ocular inflammatory disorders.
  • Initial data provides insights into potential ocular surface adverse effects.
  • These agents offer a more targeted approach compared to broad anti-inflammatory drugs.

Conclusions:

  • Immunobiologicals represent a promising therapeutic avenue for ocular inflammatory diseases.
  • Understanding immunopathophysiology of ocular surface disorders is crucial for optimizing treatment.
  • Further research is needed to fully elucidate the benefits and risks of immunobiologicals in ophthalmology.